Stallergenes Greer

STAGR

GB00BZ21RF93

Pharmaceuticals

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+0.14%	+29.68%

2023	Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	CI
2023	Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	CI

Stallergenes Greer plc Reports Unaudited Revenue Results for the First Quarter of 2019; Confirms Earnings Guidance for the Full Year 2019

April 17, 2019 at 01:30 am EDT

Stallergenes Greer plc reported unaudited revenue results for the first quarter of 2019. For the quarter, the company reported net sales of €84.7 million against €76.2 million a year ago.

The company confirms its full year outlook for 2019 for net sales to be in the range of €290 million to €300 million.

Latest news about Stallergenes Greer

Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	23-07-11	CI
Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	23-05-25	CI
Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-05	CI
Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration	22-01-17	CI
Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery	21-10-26	CI
Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy	21-07-09	CI
Stallergenes Greer Ltd Announces Alustal®, Subcutaneous Allergen Immunotherapy Treatment Now Available	21-06-24	CI
Stallergenes Greer and Anergis Report Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergen Immunotherapy	20-05-28	CI
Stallergenes Greer Announces Submission of A Marketing Authorization Application for STAGR320	20-05-04	CI
Stallergenes Greer plc(ENXTPA:STAGR) dropped from CAC All-Tradable Index	19-05-16	CI
Stallergenes Greer plc(ENXTPA:STAGR) dropped from CAC Small Index	19-05-16	CI
Stallergenes Greer plc(ENXTPA:STAGR) dropped from CAC Small Index	19-05-16	CI
Ares Life Sciences I SARL completed the acquisition of remaining 16.13% stake in Stallergenes Greer plc from a group of shareholders.	19-05-15	CI
Stallergenes Greer plc Reports Unaudited Revenue Results for the First Quarter of 2019; Confirms Earnings Guidance for the Full Year 2019	19-04-17	CI
Transcript : Stallergenes Greer plc, 2018 Earnings Call, Mar 21, 2019	19-03-21
French healthcare group Stallergenes to be bought out by Bertarelli vehicle	19-03-21	RE
Stallergenes Greer Reports Consolidated Earnings Results for the Year Ended December 31, 2018; Provides Earnings Guidance for the Full Year 2019	19-03-21	CI
Ares Life Sciences I SARL reached an agreement to acquire remaining 16.13% stake in Stallergenes Greer plc from a group of shareholders for approximately €120 million.	19-03-20	CI
Stallergenes Greer plc Announces Unaudited Sales Results for the Full Year Ended December 31, 2018	19-02-13	CI
Stallergenes Greer Announces Management Changes	18-12-12	CI
Stallergenes Greer plc Announces Phase III Trial for its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved its Primary Endpoint	18-11-20	CI
Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy	18-11-14	CI
Stallergenes Greer plc(ENXTPA:STAGR) added to CAC All-Tradable Index	18-09-24	CI
Stallergenes Greer plc(ENXTPA:STAGR) added to CAC Small Index	18-09-24	CI
Transcript : Stallergenes Greer Plc, H1 2018 Earnings Call, Aug 30, 2018	18-08-30

Chart Stallergenes Greer

Duration

Period

More charts

Company Profile

Stallergenes Greer Ltd is a United States-based holding company. The Company is a healthcare company. Its engaged in the diagnosis and treatment of allergies through the development and commercialization of allergen immunotherapy products and services. It also engaged in distribution of products and services.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
STALLERGENES GREER	+29.68%	0
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B